sharon sanders
Editor-in-Chief & President
Close relatives of MERS-CoV in bats use ACE2 as their functional receptors
View ORCID ProfileHuan Yan, View ORCID ProfileXiangxi Wang, Qing Xiong, View ORCID ProfileLei Cao, Chengbao Ma, Chen Liu, Junyu Si, Peng Liu, Mengxue Gu, Chunli Wang, Lulu Shi, Fei Tong, Meiling Huang, Chufeng Zhao, Jing Li, View ORCID ProfileChao Shen, View ORCID ProfileYu Chen, View ORCID ProfileHuabin Zhao, View ORCID ProfileKe Lan
doi: https://doi.org/10.1101/2022.01.24.477490
This article is a preprint and has not been certified by peer review [what does this mean?].
0000150313
Abstract
Middle East Respiratory Syndrome coronavirus (MERS-CoV) and several bat coronaviruses employ Dipeptidyl peptidase-4 (DPP4) as their functional receptors. However, the receptor for NeoCoV, the closest MERS-CoV relative yet discovered in bats, remains enigmatic. In this study, we unexpectedly found that NeoCoV and its close relative, PDF-2180-CoV, can efficiently use some types of bat Angiotensin-converting enzyme 2 (ACE2) and, less favorably, human ACE2 for entry. The two viruses use their spikes' S1 subunit carboxyl-terminal domains (S1-CTD) for high-affinity and species-specific ACE2 binding. Cryo-electron microscopy analysis revealed a novel coronavirus-ACE2 binding interface and a protein-glycan interaction, distinct from other known ACE2-using viruses. We identified a molecular determinant close to the viral binding interface that restricts human ACE2 from supporting NeoCoV infection, especially around residue Asp338. Conversely, NeoCoV efficiently infects human ACE2 expressing cells after a T510F mutation on the receptor-binding motif (RBM). Notably, the infection could not be cross-neutralized by antibodies targeting SARS-CoV-2 or MERS-CoV.
Our study demonstrates the first case of ACE2 usage in MERS-related viruses, shedding light on a potential bio-safety threat of the human emergence of an ACE2 using 'MERS-CoV-2' with both high fatality and transmission rate.
https://www.biorxiv.org/content/10.1101/2022.01.24.477490v1
View ORCID ProfileHuan Yan, View ORCID ProfileXiangxi Wang, Qing Xiong, View ORCID ProfileLei Cao, Chengbao Ma, Chen Liu, Junyu Si, Peng Liu, Mengxue Gu, Chunli Wang, Lulu Shi, Fei Tong, Meiling Huang, Chufeng Zhao, Jing Li, View ORCID ProfileChao Shen, View ORCID ProfileYu Chen, View ORCID ProfileHuabin Zhao, View ORCID ProfileKe Lan
doi: https://doi.org/10.1101/2022.01.24.477490
This article is a preprint and has not been certified by peer review [what does this mean?].
0000150313
Abstract
Middle East Respiratory Syndrome coronavirus (MERS-CoV) and several bat coronaviruses employ Dipeptidyl peptidase-4 (DPP4) as their functional receptors. However, the receptor for NeoCoV, the closest MERS-CoV relative yet discovered in bats, remains enigmatic. In this study, we unexpectedly found that NeoCoV and its close relative, PDF-2180-CoV, can efficiently use some types of bat Angiotensin-converting enzyme 2 (ACE2) and, less favorably, human ACE2 for entry. The two viruses use their spikes' S1 subunit carboxyl-terminal domains (S1-CTD) for high-affinity and species-specific ACE2 binding. Cryo-electron microscopy analysis revealed a novel coronavirus-ACE2 binding interface and a protein-glycan interaction, distinct from other known ACE2-using viruses. We identified a molecular determinant close to the viral binding interface that restricts human ACE2 from supporting NeoCoV infection, especially around residue Asp338. Conversely, NeoCoV efficiently infects human ACE2 expressing cells after a T510F mutation on the receptor-binding motif (RBM). Notably, the infection could not be cross-neutralized by antibodies targeting SARS-CoV-2 or MERS-CoV.
Our study demonstrates the first case of ACE2 usage in MERS-related viruses, shedding light on a potential bio-safety threat of the human emergence of an ACE2 using 'MERS-CoV-2' with both high fatality and transmission rate.
https://www.biorxiv.org/content/10.1101/2022.01.24.477490v1